A danazol-loaded intrauterine device decreases dysmenorrhea, pelvic pain, and dyspareunia associated with endometriosis
- PMID: 15237024
- DOI: 10.1016/j.fertnstert.2003.11.058
A danazol-loaded intrauterine device decreases dysmenorrhea, pelvic pain, and dyspareunia associated with endometriosis
Abstract
A danazol-loaded intrauterine device (IUD) containing 300-400 mg of danazol was inserted for 6 months in a group of women (n = 18) (median age 36.6 years; age range: 30 to 46 years) with a histologic diagnosis of endometriosis, referred for recurrent pelvic pain. Dysmenorrhea, dyspareunia, and pelvic pain significantly decreased after the first month, with a persistent effect during the 6 months of IUD insertion. These results show that a danazol-loaded IUD is an effective conservative therapy for patients with endometriosis-related pelvic pain.
Similar articles
-
Pain of endometriosis: effects of nafarelin and danazol therapy.Int J Fertil Menopausal Stud. 1994 Jul-Aug;39(4):215-7. Int J Fertil Menopausal Stud. 1994. PMID: 7951404 Clinical Trial.
-
Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial.Obstet Gynecol. 2012 Mar;119(3):519-26. doi: 10.1097/AOG.0b013e31824264c3. Obstet Gynecol. 2012. PMID: 22314873 Clinical Trial.
-
Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis.Hum Reprod. 2009 Dec;24(12):3033-41. doi: 10.1093/humrep/dep302. Epub 2009 Sep 2. Hum Reprod. 2009. PMID: 19726448 Clinical Trial.
-
Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea.Contraception. 2007 Jun;75(6 Suppl):S134-9. doi: 10.1016/j.contraception.2006.12.008. Epub 2007 Feb 16. Contraception. 2007. PMID: 17531605 Review.
-
[Local administration of danazol on pelvic endometriosis and uterine adenomyosis].Nihon Rinsho. 2001 Jan;59 Suppl 1:153-6. Nihon Rinsho. 2001. PMID: 11235155 Review. Japanese. No abstract available.
Cited by
-
Androgen Signaling in Uterine Diseases: New Insights and New Targets.Biomolecules. 2022 Nov 3;12(11):1624. doi: 10.3390/biom12111624. Biomolecules. 2022. PMID: 36358974 Free PMC article. Review.
-
Hormonal treatments for endometriosis: The endocrine background.Rev Endocr Metab Disord. 2022 Jun;23(3):333-355. doi: 10.1007/s11154-021-09666-w. Epub 2021 Aug 17. Rev Endocr Metab Disord. 2022. PMID: 34405378 Free PMC article. Review.
-
Endometriosis: current therapies and new pharmacological developments.Drugs. 2009;69(6):649-75. doi: 10.2165/00003495-200969060-00002. Drugs. 2009. PMID: 19405548 Review.
-
Interventions for women with endometrioma prior to assisted reproductive technology.Cochrane Database Syst Rev. 2010 Nov 10;2010(11):CD008571. doi: 10.1002/14651858.CD008571.pub2. Cochrane Database Syst Rev. 2010. PMID: 21069706 Free PMC article.
-
Decoding connections in the European population: serum uric acid, sex hormone-binding globulin, total testosterone, estradiol, and female infertility - advanced bidirectional and mediative Mendelian randomization.Front Endocrinol (Lausanne). 2024 Jun 28;15:1398600. doi: 10.3389/fendo.2024.1398600. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39006368 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical